Role of Histone Acetylation Modification in Posttranscriptional Gene Expression

GUAN Xiao-xiang,CHEN Long-bang
DOI: https://doi.org/10.3969/j.issn.1673-5269.2007.04.020
2007-01-01
Abstract:The term epigenetics encompasses all the modifications that are stable across cell generations, but which do not imply any change in DNA sequence. Post-translational modifications of the histones and DNA methylation are the most studied types of epigenetic information due to their major impact on transcription.Epigenetic deregulations may play a critical role in the tumorigenesis. Recent studies have demonstrated that the histone modification is important epigenetic mechanisms of gene regulation and plays essential roles both independently and cooperatively in tumor initiation and progression. Imbalance in histone acetylation can lead to transcriptional dysregulation of genes that are involved in the control of proliferation, cell-cycle progression, differentiation and apoptosis. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are two classes of enzymes regulating histone acetylation and whose altered activities have been identified in several cancers. HATs and HDACs determine the acetylation status of histones. This acetylation affects the regulation of gene expression, and inhibitors of HDACs have been found to cause growth arrest, differentiation and apoptosis of many tumours cells by altering the transcription of a small number of genes.The current research raises the possibility that histone deacetylase inhibitors (HDAIs) may prove potent effective in the treatment of cancers. HDAIs could enhance the therapeutic window for clinical applications and open up a highly specific new option for cancer treatment. In this review, we examine the current literatures on epigenetic changes in cancer and discuss the clinical potential of histone deacetylase inhibitors for treatment of cancer.
What problem does this paper attempt to address?